<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179268</url>
  </required_header>
  <id_info>
    <org_study_id>[2012] NO31260237/C090103</org_study_id>
    <nct_id>NCT02179268</nct_id>
  </id_info>
  <brief_title>Antidepressants and Bone Mineral Density</brief_title>
  <official_title>International Committee of Medical Journal Editors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guiyang Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guiyang Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this five arm randomized trial was thus to compare selective serotonin reuptake
      inhibitor (SSRI)sertraline and citalopram to a dual reuptake inhibitor venlafaxine, a
      nor-adrenaline reuptake inhibitor reboxetine and a control group receiving placebo, with the
      primary endpoint being bone mineral density, and secondary endpoints being bone turnover
      markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      These results have overt clinical implications. They suggest a noxious effect, particularly
      of selective serotonin reuptake inhibitor (SSRI) antidepressants, on bone. Osteoporosis and
      fracture is overtly the problem of the elderly. However, the process of skeletal
      consolidation begins in childhood and the corresponding phase of demineralisation proceeds at
      a glacial pace and lasts throughout adulthood, as a consequence antidepressant therapy is
      likely to have a substantive impact on a phenomenon likely to manifest decades hence. It is
      known that numerically small changes in bone mineral density are associated with a
      substantial increase in fracture risk. Because the SSRIs have only been in widespread use for
      two decades, it is plausible that the consequences of this adverse effect are yet to emerge.
      These data consequently suggest a recalibration of the risk/benefit ratio of this class of
      agents and additionally beg the question of the potential role of screening for bone mineral
      density in this at-risk population group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density (BMD)</measure>
    <time_frame>Change from Baseline in bone mineral density at one year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Bone Mineral Density Quantitative Trait Locus 7</condition>
  <arm_group>
    <arm_group_label>sertraline &amp; control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>citalopram &amp; Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>venlafaxine &amp; control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>reboxetine &amp; control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
    <description>50mg, 50-150mg/d,qd for one year</description>
    <arm_group_label>sertraline &amp; control</arm_group_label>
    <arm_group_label>citalopram &amp; Control</arm_group_label>
    <arm_group_label>venlafaxine &amp; control</arm_group_label>
    <arm_group_label>reboxetine &amp; control</arm_group_label>
    <other_name>Zoloff</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <description>20mg, 20-40mg/d,qd,for one year</description>
    <arm_group_label>sertraline &amp; control</arm_group_label>
    <arm_group_label>citalopram &amp; Control</arm_group_label>
    <arm_group_label>venlafaxine &amp; control</arm_group_label>
    <arm_group_label>reboxetine &amp; control</arm_group_label>
    <other_name>Cipramil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
    <description>venlafaxine,25mg, 75-100mg/d, bid, for one year</description>
    <arm_group_label>sertraline &amp; control</arm_group_label>
    <arm_group_label>citalopram &amp; Control</arm_group_label>
    <arm_group_label>venlafaxine &amp; control</arm_group_label>
    <arm_group_label>reboxetine &amp; control</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reboxetine</intervention_name>
    <description>reboxetine,4mg, 4-8mg/d,qd for one year</description>
    <arm_group_label>sertraline &amp; control</arm_group_label>
    <arm_group_label>citalopram &amp; Control</arm_group_label>
    <arm_group_label>venlafaxine &amp; control</arm_group_label>
    <arm_group_label>reboxetine &amp; control</arm_group_label>
    <other_name>Edronax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>control</intervention_name>
    <description>50min, every week for three months, every month, for nine months</description>
    <arm_group_label>sertraline &amp; control</arm_group_label>
    <arm_group_label>citalopram &amp; Control</arm_group_label>
    <arm_group_label>venlafaxine &amp; control</arm_group_label>
    <arm_group_label>reboxetine &amp; control</arm_group_label>
    <other_name>cognitive behavioral therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants needed to have a primary diagnosis of depression with Zung Self Rated
             Depression Scale (SDS) &gt; 53, and Hamilton Depression Scale (HAMD) â‰¥20.

        Exclusion Criteria:

          -  The patients with hyperparathyroidism, myeloma or other disorders known to affect bone
             metabolism

          -  Use of estrogen

          -  Calcitonin drugs

          -  Previous antidepressant or other psychiatric drug use or prior treatment history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yiming wang, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>World Health Organization</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>June 28, 2014</last_update_submitted>
  <last_update_submitted_qc>June 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guiyang Medical University</investigator_affiliation>
    <investigator_full_name>Yiming Wang</investigator_full_name>
    <investigator_title>Department of Psychiatry, the Affiliated Hospital</investigator_title>
  </responsible_party>
  <keyword>Antidepressants</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>bone turnover markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Reboxetine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

